BMS

Bristol-Myers Squibb (BMS) has entered into an exclusive option agreement to acquire Denmark-based Galecto Biotech and receive worldwide rights to its inhaled inhibitor of galectin-3, TD139.

Galectin-3 is a protein that binds to carbohydrate structures in the body, and plays a crucial role in various types of fibrosis.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

TD139 is currently in Phase I development for the treatment of idiopathic pulmonary fibrosis (IPF) and other pulmonary fibrotic conditions.

Including the option fee, an option exercise fee and subsequent clinical and regulatory milestone payments, total aggregate payments under the deal are expected to be $444m.

Bristol-Myers Squibb executive vice-president Francis Cuss said: "Delivering innovative medicines that halt or slow the progression of fibrotic diseases is a key part of our R&D strategy to build a sustainable pipeline.

See Also:

"As part of the deal, BMS can exercise the option to acquire Galecto no later than 60 days following completion of the Phase Ib trial."

"TD139 provides Bristol-Myers Squibb an opportunity to advance the company’s fibrosis development program with the addition of a promising compound that has the potential to modulate multiple disease pathways."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

As part of the deal, BMS can exercise the option to acquire Galecto no later than 60 days following completion of the Phase Ib trial.

Both companies agreed on pre-clinical studies and a Phase I development plan, which will be carried out by Galecto during the option period.

Galecto Biotech CEO Hans Schambye said: "Galecto, in close collaboration with our founders, managed to demonstrate the importance of galectin-3 as an anti-fibrosis target."

BMS is involved in developing an early stage fibrosis portfolio, which includes BMS-986020, a lysophosphatidic acid 1 (LPA1) receptor antagonist in development for the treatment of IPF.

Image: Bristol-Myers-Squibb Pharmaceutical Research Institute on Reeds Lane is responsible for the discovery and development of new medicines. Photo: courtesy of Sue Adair.